1 LeMaitre Vascular, Inc. Investor Presentation Disclaimers Forward-Looking Statements This presentation contains certain forward-looking statements, within the meaning of the U.S. Private Securities Litigation Reform Act of 1995, that involve risks and uncertainties. Actual results and events may differ significantly from results and events discussed in forward-looking statements. Factors that might cause or contribute to such differences include, but are not limited to, those discussed in "Risk Factors" i ...

SECURITIES EXCHANGE ACT OF 1934 Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K (Mark One) ☑ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2020 or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE For the transition period from to . Commission File Number 001-33092 LEMAITRE VASCULAR, INC. (Exact name of registrant as specified in its charter) (State or other jurisdiction ...

LeMaitre Vascular, Inc. (NASDAQ:LMAT) Q4 2020 Earnings Conference Call February 25, 2021 5:00 PM ET Company Participants JJ Pellegrino – Chief Financial Officer George LeMaitre – Chairman and Chief Executive Officer Dave Roberts – President Conference Call Participants Rick Wise – Stifel Brett Fishbin – KeyBanc Mike Petusky – Barrington Research James Sidoti – Sidoti & Company Operator Welcome to the LeMaitre Vascular Q4 2020 Financial Results Conference Call. As a reminder, today’s call is being recorded. ...

1 LeMaitre Vascular, Inc. Investor Presentation Disclaimers Forward-Looking Statements This presentation contains certain forward-looking statements, within the meaning of the U.S. Private Securities Litigation Reform Act of 1995, that involve risks and uncertainties. Actual results and events may differ significantly from results and events discussed in forward-looking statements. Factors that might cause or contribute to such differences include, but are not limited to, those discussed in "Risk Factors" i ...

V LeMaitre® Your Peripheral Vision® Disclaimers Forward-Looking Statements This presentation contains certain forward-looking statements, within the meaning of the U.S. Private Securities Litigation Reform Act of 1995, that involve risks and uncertainties. Actual results and events may differ significantly from results and events discussed in forward-looking statements. Factors that might cause or contribute to such differences include, but are not limited to, those discussed in "Risk Factors" in our Annual ...

Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2020 Or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to . Commission File Number 001-33092 LEMAITRE VASCULAR, INC. (Exact name of registrant as specified in its charter) Delaware 04-2825458 ...

LeMaitre Vascular, Inc. (NASDAQ:LMAT) Q3 2020 Earnings Conference Call October 29, 2020 5:00 PM ET Company Participants Joseph Pellegrino - CFO George LeMaitre - Chairman and CEO David Roberts - President Conference Call Participants Frank Takkinen - Lake Street Capital Markets, LLC Andrew Ranieri - Stifel, Nicolaus & Co., Inc. Michael Petusky - Barrington Research Associates, Inc. James Sidoti - Sidoti & Company, LLC Scott Henry - ROTH Capital Operator Welcome to the LeMaitre Vascular Q3 2020 Financial Res ...

V LeMaitre® Your Peripheral Vision® Disclaimers Forward-Looking Statements This presentation contains certain forward-looking statements, within the meaning of the U.S. Private Securities Litigation Reform Act of 1995, that involve risks and uncertainties. Actual results and events may differ significantly from results and events discussed in forward-looking statements. Factors that might cause or contribute to such differences include, but are not limited to, those discussed in "Risk Factors" in our Annual ...

Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) Or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to . Commission File Number 001-33092 LEMAITRE VASCULAR, INC. (Exact name of registrant as specified in its charter) Delaware 04-2825458 (State or other jurisdiction of incorporation or organization) (I.R.S. Employer Identification No.) 63 Second Avenue, Burlington, Massachus ...

LeMaitre Vascular, Inc. (NASDAQ:LMAT) Q2 2020 Earnings Conference Call July 23, 2020 5:00 PM ET Company Participants Joseph Pellegrino - Chief Financial Officer, Treasurer and Secretary George LeMaitre - Chairman and Chief Executive Officer David Roberts - President Conference Call Participants Cecilia Furlong - Canaccord Genuity Group Inc. Andrew Ranieri - Stifel, Nicolaus & Co., Inc. Brooks O'Neil - Lake Street Capital Markets, LLC Michael Petusky - Barrington Research Associates, Inc. James Sidoti - Sido ...